The effect of atorvastatin on Covid 19

The effect of atorvastatin on on inflammatory factors and prognosis outcomes in patients with Covid 19, hospitalized in Hajar Hospital, Shahrekord University of Medical Sciences, 2021

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210426051090N1

Enrollment

Registered

2021-06-12

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Control group: Patients receiving standard diet treatment (according to national protocol) + placebo. Intervention 2: Intervention group: Patients with standard diet treatment + atorva

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with confirmed molecular test of blood oxygen saturation level SpO2 less than 90% in room air Patients with pulmonary involvement in radiological studies Do not take statins The patient is not in a state of shock and sepsis

Exclusion criteria

Exclusion criteria: Having advanced heart disease (CHF) Liver disease (based on primary LFT) Incidence of statin side effects Long-term use of corticosteroids to die Pulmonary underlying disease

Design outcomes

Primary

Measure	Time frame
O2 Saturation. Timepoint: 1 and 7 days after the start of the study. Method of measurement: Pulse oximetry device.;FBS. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;IL-6. Timepoint: 1 and 14 days after the start of the study. Method of measurement: blood test.;Alt? Ast ?Alkp ? Bill total ? Bill direct. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;BUN, Na, K, Cr. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;PT, PTT, INR. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;TG, Total Cholesterol, LDL, HDL. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;CBC(diff). Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;LDH. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;ESR. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;CRP. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;Ferritin. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.	—

Measure

Time frame

O2 Saturation. Timepoint: 1 and 7 days after the start of the study. Method of measurement: Pulse oximetry device.;FBS. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;IL-6. Timepoint: 1 and 14 days after the start of the study. Method of measurement: blood test.;Alt? Ast ?Alkp ? Bill total ? Bill direct. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;BUN, Na, K, Cr. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;PT, PTT, INR. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;TG, Total Cholesterol, LDL, HDL. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;CBC(diff). Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test.;LDH. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;ESR. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;CRP. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.;Ferritin. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahab Moghaddam

Shahre-kord University of Medical Sciences

st-moghaddam.sh@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026